The Cell Therapy Biomanufacturing Market size was estimated at USD 8.46 billion in 2025 and expected to reach USD 9.75 billion in 2026, at a CAGR of 16.46% to reach USD 24.60 billion by 2032.

Market Leader: Asahi Kasei Corporation leads with 0.00%, ahead of notable competitors including bluebird bio, Inc., Bristol Myers Squibb Company, Catalent, Inc., and Celgene Corporation, among others.
Market Segmentation: The market is segmented by Manufacturing Model, Therapy Area, Process Stage, and Cell Type, offering actionable insights to guide focused growth strategies.
Analytical Highlights: The report delivers in-depth analysis on the Cumulative Impact of Artificial Intelligence (2025), alongside Market Share Analysis, the FPNV Positioning Matrix, and a comprehensive Competitive Analysis. These insights provide clear, actionable guidance on company strategies and evolving market dynamics.

The comprehensive market research report contains extensive data points and includes granular segmentation, key trends, competitive benchmarking, and opportunity mapping to deliver clear, actionable insights. It also provides substantial analytical depth through Market Share Analysis, the FPNV Positioning Matrix, and detailed Company Strategy analysis.

Additionally, the market research report highlights country-level growth patterns, policy and investment impacts, regional market potential, and geopolitical dynamics that shape demand and market access.

Cell Therapy Biomanufacturing Market - Global Forecast 2026-2032